UK pharma major GSK (LSE: GSK) has unveiled full Phase III data showing its experimental drug linerixibat significantly reduced itching in people with primary biliary cholangitis (PBC), a rare autoimmune liver disorder. The results were presented at this year’s European Association for the Study of the Liver (EASL) meeting.
The late-stage trial, known as GLISTEN, involved 238 adults with moderate-to-severe cholestatic pruritus — an intense internal itching — and met its primary goal, with patients on linerixibat reporting a notable drop in itch severity over 24 weeks compared to placebo.
Linerixibat users recorded an average placebo-adjusted improvement of 0.72 points on a 10-point itch scale. Key secondary outcomes also hit the mark, with over half of those on the drug benefitting from a clinically meaningful improvement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze